Tag: mCRPC

EAU15: mCRPC looks at novel research

Much research has been done on new treatment modalities for patients with metastatic castration-resistant prostate cancer (mCRPC) but the cross resistance between these therapies needs to be understood better. Another relative new topic of research is the quality of...

Do we need to continue androgen deprivation therapy?

Fortunately, a growing number of treatment options exist to treat metastatic castrate-resistant prostate cancer (mCRPC); however, with these newer options many questions about optimising treatment remain unanswered. There is an on-going discussion on the value and need of androgen...

Where do we stand with predictive biomarkers in mCRPC?

Treatment options for men with metastatic castrationresistant prostate cancer (mCRPC) have expanded with the introduction of several new approved agents including abiraterone, enzalutamide, cabazitaxel and radium-2231-6. With evidence that both abiraterone acetate and enzalutamide are effective agents when administered...